# US 2026/0166178 A1 · Manipulating golgi ions for treatment of neurodegenerative disease and cutaneous disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0166178 A1
- Document ID: US20260166178A1
- Status: Published application
- Kind: A1
- Application number: 19/543,607
- Filed: 2026-02-18
- Published: 2026-06-18
- Earliest claimed: 2024-08-19
- Assignees: The Johns Hopkins University; Formation Venture Engineering Foundry, Inc.
- Applicants: The Johns Hopkins University; Formation Venture Engineering Foundry, Inc.
- Inventors: Rajini Rao; Ruby Gupta; Ajay Verma
- Web page: https://patentgrep.com/patent/US20260166178A1

## CPC

- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- A61K 38/43: Enzymes; Proenzymes; Derivatives thereof
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C12N 9/16: acting on ester bonds (3.1)
- C12N 15/86: Viral vectors
- C12Y 306/03008: Ca2+-transporting ATPase (3.6.3.8)
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 25/00: Drugs for disorders of the nervous system
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

The invention provides that the expression and/or activity of metal ion transporter, such as a Ca2+/Mn2+ transporter and secretory pathway calcium ATPase 1 (SPCA1) or SPCA2 is associated with the restoration and conservation of Golgi integrity in cells, as well as with the restoration of Golgi ion concentrations. Provided herein are methods of restoring or maintaining Golgi integrity in a cell and methods of modulating Golgi ion concentration is a cell including increasing the expression and/or activity of a metal ion transporter such as SPCA1 or SPCA2 protein in the cell. The invention further provides methods of treating neurodegenerative disease, such as amyotrophic lateral sclerosis (ALS). The methods of treatment include increasing the expression and/or activity of a metal ion transporter such as SPCA1 or SPCA2 protein in cells to restore or maintain Golgi integrity and Golgi ion concentration in the cell.

## Claims

### Claim 1

A method of maintaining and/or restoring Golgi integrity in a cell comprising increasing the expression and/or activity of a metal ion transporter in the cell, thereby maintaining and/or restoring Golgi integrity in the cell.

### Claim 2 (depends on 1)

The method of claim 1, wherein the metal ion transporter is a Ca2+/Mn2+ transporter.

### Claim 3 (depends on 2)

The method of claim 2, wherein the Ca2+/Mn2+ transporter is a secretory pathway calcium ATPase (SPCA) protein.

### Claim 4 (depends on 3)

The method of claim 3, wherein the SPCA protein is SPCA1 or SPCA2.

### Claim 5 (depends on 4)

The method of claim 4, wherein increasing SPCA1 or SPCA2 expression and/or activity in the cell comprises contacting the cell with a vector comprising a nucleic acid encoding a SPCA1 or SPCA2 protein.

### Claim 6 (depends on 5)

The method of claim 5, wherein the vector is an adeno-associated virus (AAV) vector, optionally wherein the vector is an AAV9 vector or an AAV2 vector.

### Claim 7 (depends on 6)

The method of claim 6, wherein the AAV vector comprises SEQ ID NO: 7, SEQ ID NO:8, SEQ ID NO:1 or SEQ ID NO:2.

### Claim 8 (depends on 4)

The method of claim 4, wherein increasing SPCA1 or SPCA2 expression and/or activity in the cell comprises contacting the cell with a small molecule agonist or activator of SPCA1 or SPCA2.

### Claim 9

A method of modulating Golgi ion concentration in a cell comprising increasing the expression and/or activity of a metal ion transporter in the cell, thereby modulating Golgi ion concentration in the cell.

### Claim 10 (depends on 9)

The method of claim 9, wherein modulating Golgi ion concentration in the cell comprises (i) increasing Ca2+ and/or Mn2+ concentration in the Golgi, (ii) decreasing Ca2+ and/or Mn2+ in the cytoplasm, (iii) restoring Golgi Ca2+ and/or Mn2+ level and/or (iv) increasing cytoplasmic Ca2+ and/or Mn2+ clearance rate in the cell.

### Claim 11

A method of treating a neurodegenerative disease in subject comprising increasing the expression and/or activity of a metal ion transporter in the subject, thereby treating the neurodegenerative disease.

### Claim 12 (depends on 11)

The method of claim 11, wherein increasing the expression and/or activity of a metal ion transporter in the subject comprises increasing SPCA1 or SPCA2 expression and/or activity in a cell from the subject.

### Claim 13 (depends on 12)

The method of claim 12, wherein increasing SPCA1 or SPCA2 expression and/or activity in a cell comprises (i) maintaining and/or restoring Golgi integrity in the cell, (ii) decreasing Golgi fragmentation in the cell, (iii) decreasing mitochondrial depolarization in the cell, (iv) decreasing oxidative stress in the cell, (v) decreasing ROS production in the cell, (vi) increasing cell viability, (vii) decreasing cholesterol accumulation in the cell, (viii) improving sorting, processing and/or secretion and post-translational modification of cargo protein in the cell, (ix) modulating ionic concentration in a Golgi lumen in the cell, (x) protecting the cell against damage, (xi) increasing Ca2+ and/or Mn2+ concentration in the Golgi in the cell, (xii) decreasing Ca2+ and/or Mn2+ in the cytoplasm in the cell, (xiii) restoring Golgi Ca2+ and/or Mn2+ level in the cell, (xiv) increasing cytoplasmic Ca2+ and/or Mn2+ clearance rate in the cell, (xv) maintaining nuclear localization of TDP-43 in the cell, (xvi) correcting cytoplasmic mislocalization of TDP-43 in the cell, or (xvii) any combination thereof.

### Claim 14 (depends on 12)

The method of claim 12, wherein increasing SPCA1 or SPCA2 expression and/or activity in the cell from the subject comprises contacting the cell with a vector comprising a nucleic acid encoding a SPCA1 or SPCA2 protein.

### Claim 15 (depends on 14)

The method of claim 14, wherein the vector is an adeno-associated virus (AAV) vector, optionally wherein the vector is an AAV9 vector.

### Claim 16 (depends on 15)

The method of claim 15, wherein the AAV vector comprises SEQ ID NO: 7, SEQ ID NO:8, SEQ ID NO:1 or SEQ ID NO:2.

### Claim 17 (depends on 1)

The method of claim 1, wherein the neurodegenerative disease is selected from the group consisting of amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), frontotemporal dementia (FTD), Huntington's disease (HD), Creutzfeldt-Jakob disease (CJD) and Parkinson's disease (PD).

### Claim 18

A method of treating amyotrophic lateral sclerosis (ALS), in a subject comprising increasing the expression and/or activity of a secretory pathway calcium ATPase (SPCA) protein in the subject, thereby treating ALS.

### Claim 19 (depends on 18)

The method of claim 18, wherein increasing SPCA1 or SPCA2 expression and/or activity in the cell from the subject comprises contacting the cell with a vector comprising a nucleic acid encoding a SPCA1 or SPCA2 protein, wherein the vector is an adeno-associated virus (AAV) vector.

### Claim 20 (depends on 19)

The method of claim 19, wherein the vector is an AAV9 vector.

### Claim 21 (depends on 19)

The method of claim 19, wherein the AAV vector comprises SEQ ID NO: 7, SEQ ID NO:8, SEQ ID NO:1 or SEQ ID NO:2.

### Claim 22 (depends on 18)

The method of claim 18, wherein treating ALS comprises improving hindlimb weakness and paralysis, inhibiting forelimb issues, inhibiting muscle atrophy, increasing grip, reducing tremors, improving posture, inhibiting weight loss, and/or inhibiting paralysis in the subject.
